ID   RN213_HUMAN             Reviewed;        5207 AA.
AC   Q63HN8; C9JCP4; D6RI12; F8WKS1; Q658P6; Q69YK7; Q6MZR1; Q8IWF4; Q8IZX1;
AC   Q8IZX2; Q8N406; Q8TEU0; Q9H6C9; Q9H6H9; Q9H6P3; Q9H8A9; Q9HCF4; Q9HCL8;
DT   20-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   21-MAR-2012, sequence version 3.
DT   10-APR-2019, entry version 145.
DE   RecName: Full=E3 ubiquitin-protein ligase RNF213 {ECO:0000305};
DE            EC=2.3.2.27 {ECO:0000269|PubMed:21799892};
DE            EC=3.6.4.- {ECO:0000269|PubMed:21799892};
DE   AltName: Full=ALK lymphoma oligomerization partner on chromosome 17 {ECO:0000303|PubMed:12112524};
DE   AltName: Full=Mysterin {ECO:0000303|PubMed:26126547};
DE   AltName: Full=RING finger protein 213 {ECO:0000305};
DE   AltName: Full=RING-type E3 ubiquitin transferase RNF213 {ECO:0000305};
GN   Name=RNF213 {ECO:0000312|HGNC:HGNC:14539};
GN   Synonyms=ALO17 {ECO:0000303|PubMed:12112524}, C17orf27
GN   {ECO:0000312|HGNC:HGNC:14539}, KIAA1554 {ECO:0000303|PubMed:10997877},
GN   KIAA1618 {ECO:0000303|PubMed:10997877}, MYSTR
GN   {ECO:0000303|PubMed:26126547};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   AUTOUBIQUITINATION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, VARIANTS
RP   ASP-3962; GLN-4062; SER-4608; ASN-4863; ASP-4950; VAL-5021; GLU-5160 AND
RP   GLY-5176, AND VARIANTS MYMY2 ASN-4013 AND LYS-4810.
RX   PubMed=21799892; DOI=10.1371/journal.pone.0022542;
RA   Liu W., Morito D., Takashima S., Mineharu Y., Kobayashi H., Hitomi T.,
RA   Hashikata H., Matsuura N., Yamazaki S., Toyoda A., Kikuta K., Takagi Y.,
RA   Harada K.H., Fujiyama A., Herzig R., Krischek B., Zou L., Kim J.E.,
RA   Kitakaze M., Miyamoto S., Nagata K., Hashimoto N., Koizumi A.;
RT   "Identification of RNF213 as a susceptibility gene for moyamoya disease and
RT   its possible role in vascular development.";
RL   PLoS ONE 6:E22542-E22542(2011).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 3021-5207 (ISOFORMS 1/2).
RC   TISSUE=Endometrium, Lymph node, Melanoma, and Uterus;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Blocker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Kohrer K., Ottenwalder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4).
RC   TISSUE=Eye, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M., Peck A.M.,
RA   Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S., Feolo M.,
RA   Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F., Schaefer C.F.,
RA   Buetow K., Bonner T.I., Haussler D., Kent J., Kiekhaus M., Furey T.,
RA   Brent M., Prange C., Schreiber K., Shapiro N., Bhat N.K., Hopkins R.F.,
RA   Hsie F., Driscoll T., Soares M.B., Casavant T.L., Scheetz T.E.,
RA   Brown-stein M.J., Usdin T.B., Toshiyuki S., Carninci P., Piao Y.,
RA   Dudekula D.B., Ko M.S., Kawakami K., Suzuki Y., Sugano S., Gruber C.E.,
RA   Smith M.R., Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y.,
RA   Wei C.L., Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W.,
RA   Fuh E., Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D., Granite S.J.,
RA   Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G., Blakesly R.W.,
RA   Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J.,
RA   Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L., Krzywinski M.I.,
RA   Liao N., Morin R., Morrin R., Palmquist D., Petrescu A.S., Skalska U.,
RA   Smailus D.E., Stott J.M., Schnerch A., Schein J.E., Jones S.J., Holt R.A.,
RA   Baross A., Marra M.A., Clifton S., Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-163 (ISOFORMS 1 AND 2/3), AND CHROMOSOMAL
RP   TRANSLOCATION WITH ALK.
RX   PubMed=12112524; DOI=10.1002/gcc.10033;
RA   Cools J., Wlodarska I., Somers R., Mentens N., Pedeutour F., Maes B.,
RA   De Wolf-Peeters C., Pauwels P., Hagemeijer A., Marynen P.;
RT   "Identification of novel fusion partners of ALK, the anaplastic lymphoma
RT   kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic
RT   tumor.";
RL   Genes Chromosomes Cancer 34:354-362(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 136-1509 AND 3888-5207 (ISOFORMS
RP   1/2).
RC   TISSUE=Brain;
RX   PubMed=10997877; DOI=10.1093/dnares/7.4.271;
RA   Nagase T., Kikuno R., Nakayama M., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVIII. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:273-281(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3770-5207 (ISOFORMS 1/2).
RC   TISSUE=Spleen, and Thyroid;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M.,
RA   Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., Moriya S.,
RA   Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., Nakagawa S.,
RA   Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., Hishigaki H.,
RA   Watanabe T., Sugiyama A., Takemoto M., Kawakami B., Yamazaki M.,
RA   Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., Komiyama M.,
RA   Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., Fujii Y.,
RA   Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., Kobatake N.,
RA   Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., Noguchi S.,
RA   Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., Mizuno T.,
RA   Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., Watanabe M.,
RA   Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y.,
RA   Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y.,
RA   Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T.,
RA   Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1258, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1258, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1258, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by enrichment
RT   and fractionation of phosphopeptides with strong anion exchange
RT   chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1258, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1258, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:ra46-RA46(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-217 AND SER-1258, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:ra3-RA3(2010).
RN   [14]
RP   INTERACTION WITH M.TUBERCULOSIS RV3655C (MICROBIAL INFECTION), AND
RP   INDUCTION (MICROBIAL INFECTION).
RX   PubMed=20454556; DOI=10.1371/journal.pone.0010474;
RA   Danelishvili L., Yamazaki Y., Selker J., Bermudez L.E.;
RT   "Secreted Mycobacterium tuberculosis Rv3654c and Rv3655c proteins
RT   participate in the suppression of macrophage apoptosis.";
RL   PLoS ONE 5:E10474-E10474(2010).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1258, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:rs3-RS3(2011).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Burckstummer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-208; SER-217 AND SER-1258,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-217; SER-1258 AND SER-2273,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1151, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [20]
RP   FUNCTION, SUBUNIT, AND MUTAGENESIS OF LYS-2426; GLU-2488; LYS-2775 AND
RP   GLU-2845.
RX   PubMed=24658080; DOI=10.1038/srep04442;
RA   Morito D., Nishikawa K., Hoseki J., Kitamura A., Kotani Y., Kiso K.,
RA   Kinjo M., Fujiyoshi Y., Nagata K.;
RT   "Moyamoya disease-associated protein mysterin/RNF213 is a novel AAA+
RT   ATPase, which dynamically changes its oligomeric state.";
RL   Sci. Rep. 4:4442-4442(2014).
RN   [21]
RP   INDUCTION.
RX   PubMed=26070522; DOI=10.1016/j.jstrokecerebrovasdis.2015.01.041;
RA   Zhao S., Gong Z., Zhang J., Xu X., Liu P., Guan W., Jing L., Peng T.,
RA   Teng J., Jia Y.;
RT   "Elevated serum microRNA Let-7c in Moyamoya disease.";
RL   J. Stroke Cerebrovasc. Dis. 24:1709-1714(2015).
RN   [22]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=26278786; DOI=10.1038/srep13191;
RA   Ohkubo K., Sakai Y., Inoue H., Akamine S., Ishizaki Y., Matsushita Y.,
RA   Sanefuji M., Torisu H., Ihara K., Sardiello M., Hara T.;
RT   "Moyamoya disease susceptibility gene RNF213 links inflammatory and
RT   angiogenic signals in endothelial cells.";
RL   Sci. Rep. 5:13191-13191(2015).
RN   [23]
RP   FUNCTION.
RX   PubMed=26766444; DOI=10.1016/j.devcel.2015.12.015;
RA   Scholz B., Korn C., Wojtarowicz J., Mogler C., Augustin I., Boutros M.,
RA   Niehrs C., Augustin H.G.;
RT   "Endothelial RSPO3 controls vascular stability and pruning through non-
RT   canonical WNT/Ca(2+)/NFAT signaling.";
RL   Dev. Cell 36:79-93(2016).
RN   [24]
RP   VARIANTS GLU-2554; VAL-3891; GLY-3915; MET-4567 AND MET-4765, AND VARIANTS
RP   MYMY2 THR-4399 AND LYS-4810.
RX   PubMed=21048783; DOI=10.1038/jhg.2010.132;
RA   Kamada F., Aoki Y., Narisawa A., Abe Y., Komatsuzaki S., Kikuchi A.,
RA   Kanno J., Niihori T., Ono M., Ishii N., Owada Y., Fujimura M., Mashimo Y.,
RA   Suzuki Y., Hata A., Tsuchiya S., Tominaga T., Matsubara Y., Kure S.;
RT   "A genome-wide association study identifies RNF213 as the first Moyamoya
RT   disease gene.";
RL   J. Hum. Genet. 56:34-40(2011).
RN   [25]
RP   VARIANTS MYMY2 THR-4399 AND LYS-4810, AND VARIANTS ARG-4007; LEU-4367;
RP   PRO-4586; VAL-4631; ASP-4950; VAL-5021 AND ILE-5136.
RX   PubMed=23110205; DOI=10.1371/journal.pone.0048179;
RA   Wu Z., Jiang H., Zhang L., Xu X., Zhang X., Kang Z., Song D., Zhang J.,
RA   Guan M., Gu Y.;
RT   "Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han
RT   population.";
RL   PLoS ONE 7:E48179-E48179(2012).
RN   [26]
RP   CHARACTERIZATION OF VARIANT MYMY2 LYS-4810.
RX   PubMed=23994138; DOI=10.1016/j.bbrc.2013.08.067;
RA   Hitomi T., Habu T., Kobayashi H., Okuda H., Harada K.H., Osafune K.,
RA   Taura D., Sone M., Asaka I., Ameku T., Watanabe A., Kasahara T., Sudo T.,
RA   Shiota F., Hashikata H., Takagi Y., Morito D., Miyamoto S., Nakao K.,
RA   Koizumi A.;
RT   "The moyamoya disease susceptibility variant RNF213 R4810K (rs112735431)
RT   induces genomic instability by mitotic abnormality.";
RL   Biochem. Biophys. Res. Commun. 439:419-426(2013).
RN   [27]
RP   VARIANT THR-4185.
RX   PubMed=25043520; DOI=10.1111/ijs.12306;
RA   Smith K.R., Leventer R.J., Mackay M.T., Pope K., Gillies G.,
RA   Delatycki M.B., Amor D.J., Bahlo M., Lockhart P.J.;
RT   "Identification of a novel RNF213 variant in a family with heterogeneous
RT   intracerebral vasculopathy.";
RL   Int. J. Stroke 9:E26-E27(2014).
RN   [28]
RP   VARIANTS MYMY2 ASN-4013 AND LYS-4810, AND VARIANTS ALA-529 DEL; GLN-3922;
RP   TYR-3997; CYS-4019; VAL-4076; LYS-4115 DEL; GLU-4237; THR-4732 AND
RP   ILE-5163.
RX   PubMed=25278557; DOI=10.1161/STROKEAHA.114.006244;
RG   University of Washington Center for Mendelian Genomics;
RA   Cecchi A.C., Guo D., Ren Z., Flynn K., Santos-Cortez R.L., Leal S.M.,
RA   Wang G.T., Regalado E.S., Steinberg G.K., Shendure J., Bamshad M.J.,
RA   Grotta J.C., Nickerson D.A., Pannu H., Milewicz D.M.;
RT   "RNF213 rare variants in an ethnically diverse population with Moyamoya
RT   disease.";
RL   Stroke 45:3200-3207(2014).
RN   [29]
RP   VARIANT PHE-4118, AND INVOLVEMENT IN MYMY2.
RX   PubMed=26198278; DOI=10.1002/ajmg.a.37230;
RA   Harel T., Posey J.E., Graham B.H., Walkiewicz M., Yang Y., Lalani S.R.,
RA   Belmont J.W.;
RT   "Atypical presentation of moyamoya disease in an infant with a de novo
RT   RNF213 variant.";
RL   Am. J. Med. Genet. A 167A:2742-2747(2015).
RN   [30]
RP   CHARACTERIZATION OF VARIANT MYMY2 LYS-4810, FUNCTION, SUBUNIT, AND
RP   MUTAGENESIS OF GLU-2488.
RX   PubMed=26126547; DOI=10.1161/JAHA.115.002146;
RA   Kobayashi H., Matsuda Y., Hitomi T., Okuda H., Shioi H., Matsuda T.,
RA   Imai H., Sone M., Taura D., Harada K.H., Habu T., Takagi Y., Miyamoto S.,
RA   Koizumi A.;
RT   "Biochemical and functional characterization of RNF213 (Mysterin) R4810K, a
RT   susceptibility mutation of Moyamoya disease, in angiogenesis in vitro and
RT   in vivo.";
RL   J. Am. Heart. Assoc. 4:0-0(2015).
RN   [31]
RP   VARIANTS VAL-1622; MET-3933 AND CYS-4131, AND VARIANT MYMY2 LYS-4810.
RX   PubMed=25956231; DOI=10.1016/j.jns.2015.04.019;
RA   Lee M.J., Chen Y.F., Fan P.C., Wang K.C., Wang K., Wang J., Kuo M.F.;
RT   "Mutation genotypes of RNF213 gene from moyamoya patients in Taiwan.";
RL   J. Neurol. Sci. 353:161-165(2015).
RN   [32]
RP   VARIANTS CYS-4019; LYS-4042; ALA-4146 AND LEU-4677, CHARACTERIZATION OF
RP   VARIANT MYMY2 ASN-4013, AND CHARACTERIZATION OF VARIANTS CYS-4019 AND
RP   ALA-4146.
RX   PubMed=27736983; DOI=10.1371/journal.pone.0164759;
RA   Kobayashi H., Brozman M., Kyselova K., Viszlayova D., Morimoto T.,
RA   Roubec M., Skoloudik D., Petrovicova A., Juskanic D., Strauss J., Halaj M.,
RA   Kurray P., Hranai M., Harada K.H., Inoue S., Yoshida Y., Habu T.,
RA   Herzig R., Youssefian S., Koizumi A.;
RT   "RNF213 rare variants in Slovakian and Czech moyamoya disease patients.";
RL   PLoS ONE 11:E0164759-E0164759(2016).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase involved in angiogenesis
CC       (PubMed:21799892, PubMed:26278786, PubMed:26766444, PubMed:26126547).
CC       Involved in the non-canonical Wnt signaling pathway in vascular
CC       development: acts by mediating ubiquitination and degradation of FLNA
CC       and NFATC2 downstream of RSPO3, leading to inhibit the non-canonical
CC       Wnt signaling pathway and promoting vessel regression
CC       (PubMed:26766444). Also has ATPase activity (PubMed:24658080,
CC       PubMed:26126547). {ECO:0000269|PubMed:21799892,
CC       ECO:0000269|PubMed:24658080, ECO:0000269|PubMed:26126547,
CC       ECO:0000269|PubMed:26278786, ECO:0000269|PubMed:26766444}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000269|PubMed:21799892};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000305|PubMed:21799892}.
CC   -!- SUBUNIT: Homooligomer; probably forms homohexamers.
CC       {ECO:0000269|PubMed:24658080, ECO:0000269|PubMed:26126547}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with M.tuberculosis protein
CC       Rv3655c, which impairs caspase-8 activation and suppresses macrophage
CC       apoptosis by blocking the extrinsic pathway.
CC       {ECO:0000269|PubMed:20454556}.
CC   -!- INTERACTION:
CC       Q08379:GOLGA2; NbExp=3; IntAct=EBI-10248548, EBI-618309;
CC       Q6A162:KRT40; NbExp=3; IntAct=EBI-10248548, EBI-10171697;
CC       Q04864:REL; NbExp=3; IntAct=EBI-10248548, EBI-307352;
CC       P36406:TRIM23; NbExp=3; IntAct=EBI-10248548, EBI-740098;
CC       P14373:TRIM27; NbExp=3; IntAct=EBI-10248548, EBI-719493;
CC       Q15654:TRIP6; NbExp=3; IntAct=EBI-10248548, EBI-742327;
CC       Q5T124:UBXN11; NbExp=3; IntAct=EBI-10248548, EBI-746004;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:21799892}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q63HN8-3; Sequence=Displayed;
CC         Note=Major isoform detected in all tissues examined.;
CC       Name=2;
CC         IsoId=Q63HN8-4; Sequence=VSP_042417;
CC         Note=Minor isoform with restricted expression. Gene prediction based
CC         on partial EST data.;
CC       Name=3;
CC         IsoId=Q63HN8-5; Sequence=VSP_042418, VSP_042419;
CC       Name=4;
CC         IsoId=Q63HN8-6; Sequence=VSP_042416, VSP_042420;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed (at protein level).
CC       {ECO:0000269|PubMed:21799892}.
CC   -!- INDUCTION: Down-regulated by let-7c miRNA, which binds to the 3'-UTR
CC       transcript of RNF213 (PubMed:26070522). Induced by pro-inflammatory
CC       cytokines (PubMed:26278786). {ECO:0000269|PubMed:26070522,
CC       ECO:0000269|PubMed:26278786}.
CC   -!- INDUCTION: (Microbial infection) Is up-regulated in macrophages
CC       infected by M.tuberculosis. {ECO:0000269|PubMed:20454556}.
CC   -!- DOMAIN: The RING-type zinc finger domain is required for the ubiquitin-
CC       protein ligase activity. {ECO:0000269|PubMed:21799892}.
CC   -!- PTM: Autoubiquitinated. {ECO:0000269|PubMed:21799892}.
CC   -!- DISEASE: Moyamoya disease 2 (MYMY2) [MIM:607151]: A progressive
CC       cerebral angiopathy characterized by bilateral intracranial carotid
CC       artery stenosis and telangiectatic vessels in the region of the basal
CC       ganglia. The abnormal vessels resemble a 'puff of smoke' (moyamoya) on
CC       cerebral angiogram. Affected individuals can develop transient ischemic
CC       attacks and/or cerebral infarction, and rupture of the collateral
CC       vessels can cause intracranial hemorrhage. Hemiplegia of sudden onset
CC       and epileptic seizures constitute the prevailing presentation in
CC       childhood, while subarachnoid bleeding occurs more frequently in
CC       adults. {ECO:0000269|PubMed:21048783, ECO:0000269|PubMed:21799892,
CC       ECO:0000269|PubMed:23110205, ECO:0000269|PubMed:23994138,
CC       ECO:0000269|PubMed:25278557, ECO:0000269|PubMed:25956231,
CC       ECO:0000269|PubMed:26126547, ECO:0000269|PubMed:26198278,
CC       ECO:0000269|PubMed:27736983}. Note=Disease susceptibility is associated
CC       with variations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving RNF213 is associated
CC       with anaplastic large-cell lymphoma (ALCL). Translocation
CC       t(2;17)(p23;q25) with ALK. {ECO:0000269|PubMed:12112524}.
CC   -!- SIMILARITY: Belongs to the AAA ATPase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH32220.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAB13444.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC       Sequence=BAB14708.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAB15212.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAB15280.1; Type=Erroneous termination; Note=Translated as Gln.; Evidence={ECO:0000305};
CC       Sequence=BAB15330.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=CAH10615.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=CAH56189.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ALO17ID480.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB537889; BAK53191.1; -; mRNA.
DR   EMBL; AL832920; CAH10615.1; ALT_FRAME; mRNA.
DR   EMBL; AL833201; CAH56308.1; -; mRNA.
DR   EMBL; BX640932; CAE45967.1; -; mRNA.
DR   EMBL; BX647946; CAH56189.1; ALT_INIT; mRNA.
DR   EMBL; AC123764; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC124319; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC032220; AAH32220.1; ALT_INIT; mRNA.
DR   EMBL; BC036891; AAH36891.1; -; mRNA.
DR   EMBL; BC040341; AAH40341.1; -; mRNA.
DR   EMBL; AF397204; AAN63520.1; -; mRNA.
DR   EMBL; AF397205; AAN63521.1; -; mRNA.
DR   EMBL; AB046774; BAB13380.1; -; mRNA.
DR   EMBL; AB046838; BAB13444.1; ALT_SEQ; mRNA.
DR   EMBL; AK023871; BAB14708.1; ALT_INIT; mRNA.
DR   EMBL; AK025676; BAB15212.1; ALT_INIT; mRNA.
DR   EMBL; AK025914; BAB15280.1; ALT_SEQ; mRNA.
DR   EMBL; AK026038; BAB15330.1; ALT_INIT; mRNA.
DR   EMBL; AK074030; BAB84856.1; -; mRNA.
DR   CCDS; CCDS11772.1; -. [Q63HN8-5]
DR   CCDS; CCDS58606.1; -. [Q63HN8-3]
DR   RefSeq; NP_001243000.2; NM_001256071.2.
DR   RefSeq; NP_066005.2; NM_020954.3. [Q63HN8-5]
DR   SMR; Q63HN8; -.
DR   BioGrid; 121705; 45.
DR   IntAct; Q63HN8; 18.
DR   MINT; Q63HN8; -.
DR   STRING; 9606.ENSP00000464087; -.
DR   iPTMnet; Q63HN8; -.
DR   PhosphoSitePlus; Q63HN8; -.
DR   SwissPalm; Q63HN8; -.
DR   BioMuta; RNF213; -.
DR   DMDM; 380865458; -.
DR   EPD; Q63HN8; -.
DR   jPOST; Q63HN8; -.
DR   MaxQB; Q63HN8; -.
DR   PaxDb; Q63HN8; -.
DR   PeptideAtlas; Q63HN8; -.
DR   PRIDE; Q63HN8; -.
DR   ProteomicsDB; 65884; -.
DR   ProteomicsDB; 65885; -. [Q63HN8-4]
DR   ProteomicsDB; 65886; -. [Q63HN8-5]
DR   ProteomicsDB; 65887; -. [Q63HN8-6]
DR   DNASU; 57674; -.
DR   Ensembl; ENST00000319921; ENSP00000324392; ENSG00000173821. [Q63HN8-5]
DR   GeneID; 57674; -.
DR   KEGG; hsa:57674; -.
DR   UCSC; uc002jyf.5; human. [Q63HN8-3]
DR   CTD; 57674; -.
DR   DisGeNET; 57674; -.
DR   EuPathDB; HostDB:ENSG00000173821.19; -.
DR   GeneCards; RNF213; -.
DR   HGNC; HGNC:14539; RNF213.
DR   HPA; HPA003347; -.
DR   HPA; HPA026790; -.
DR   MalaCards; RNF213; -.
DR   MIM; 607151; phenotype.
DR   MIM; 613768; gene.
DR   neXtProt; NX_Q63HN8; -.
DR   OpenTargets; ENSG00000173821; -.
DR   Orphanet; 2573; Moyamoya disease.
DR   PharmGKB; PA134898812; -.
DR   PharmGKB; PA162401681; -.
DR   eggNOG; ENOG410IE7S; Eukaryota.
DR   eggNOG; ENOG410Z1EV; LUCA.
DR   GeneTree; ENSGT00630000089884; -.
DR   HOGENOM; HOG000154163; -.
DR   InParanoid; Q63HN8; -.
DR   KO; K22754; -.
DR   OrthoDB; 840at2759; -.
DR   TreeFam; TF343131; -.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; RNF213; human.
DR   GeneWiki; RNF213; -.
DR   GenomeRNAi; 57674; -.
DR   PRO; PR:Q63HN8; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000173821; Expressed in 193 organ(s), highest expression level in adult mammalian kidney.
DR   ExpressionAtlas; Q63HN8; baseline and differential.
DR   Genevisible; Q63HN8; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0016887; F:ATPase activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IMP:UniProtKB.
DR   GO; GO:2000051; P:negative regulation of non-canonical Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; TAS:Reactome.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0002040; P:sprouting angiogenesis; IMP:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR031248; RNF213.
DR   InterPro; IPR018957; Znf_C3HC4_RING-type.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR22605; PTHR22605; 1.
DR   Pfam; PF00097; zf-C3HC4; 1.
DR   SMART; SM00382; AAA; 2.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Angiogenesis; Chromosomal rearrangement; Coiled coil;
KW   Complete proteome; Cytoplasm; Disease mutation; Hydrolase; Isopeptide bond;
KW   Metal-binding; Phosphoprotein; Proto-oncogene; Reference proteome;
KW   Transferase; Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..5207
FT                   /note="E3 ubiquitin-protein ligase RNF213"
FT                   /id="PRO_0000415917"
FT   ZN_FING         3997..4036
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   COILED          343..374
FT                   /evidence="ECO:0000255"
FT   MOD_RES         208
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         217
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:23186163, ECO:0000244|PubMed:24275569"
FT   MOD_RES         1258
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18318008,
FT                   ECO:0000244|PubMed:18669648, ECO:0000244|PubMed:18691976"
FT   MOD_RES         2273
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   CROSSLNK        1151
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000244|PubMed:25218447"
FT   VAR_SEQ         1..4650
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_042416"
FT   VAR_SEQ         87
FT                   /note="E -> EGATSEVLVDAAVDLISDEWEAANAIPSKRRKQDAAPLEAASVPSAD
FT                   CEQ (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_042417"
FT   VAR_SEQ         1009..1063
FT                   /note="SQTSILQGFSYSDLRKFGIVLSAVITKSWPRTADNFNDILKHLLTLADVKHV
FT                   FRL -> VNNLSSWETDSGSQLCSAMTQLRAMKHPLGLSSSANSEIGKWAPSSLAKGNG
FT                   AEI (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:17974005"
FT                   /id="VSP_042418"
FT   VAR_SEQ         1064..5207
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:17974005"
FT                   /id="VSP_042419"
FT   VAR_SEQ         4651..4660
FT                   /note="QEQHQLSSRR -> MTRKSAPTSG (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_042420"
FT   VARIANT         529
FT                   /note="Missing (rare variant detected in a sporadic case of
FT                   Moyamoya disease in Caucasian population)"
FT                   /evidence="ECO:0000269|PubMed:25278557"
FT                   /id="VAR_075635"
FT   VARIANT         1622
FT                   /note="A -> V (rare variant detected in a sporadic case of
FT                   Moyamoya disease in East Asian population)"
FT                   /evidence="ECO:0000269|PubMed:25956231"
FT                   /id="VAR_075636"
FT   VARIANT         2554
FT                   /note="D -> E (in dbSNP:rs138516230)"
FT                   /evidence="ECO:0000269|PubMed:21048783"
FT                   /id="VAR_067020"
FT   VARIANT         3891
FT                   /note="M -> V (rare variant detected in a sporadic case of
FT                   Moyamoya disease)"
FT                   /evidence="ECO:0000269|PubMed:21048783"
FT                   /id="VAR_067021"
FT   VARIANT         3915
FT                   /note="E -> G (in dbSNP:rs61740658)"
FT                   /evidence="ECO:0000269|PubMed:21048783"
FT                   /id="VAR_067022"
FT   VARIANT         3922
FT                   /note="R -> Q (rare variant detected in a sporadic case of
FT                   Moyamoya disease in Caucasian population)"
FT                   /evidence="ECO:0000269|PubMed:25278557"
FT                   /id="VAR_075637"
FT   VARIANT         3933
FT                   /note="V -> M (rare variant detected in a sporadic case of
FT                   Moyamoya disease in East Asian population)"
FT                   /evidence="ECO:0000269|PubMed:25956231"
FT                   /id="VAR_075638"
FT   VARIANT         3962
FT                   /note="N -> D (variant detected in cases of Moyamoya
FT                   disease in Caucasian populations)"
FT                   /evidence="ECO:0000269|PubMed:21799892"
FT                   /id="VAR_067023"
FT   VARIANT         3997
FT                   /note="C -> Y (rare variant detected in a sporadic case of
FT                   Moyamoya disease in Caucasian population)"
FT                   /evidence="ECO:0000269|PubMed:25278557"
FT                   /id="VAR_075639"
FT   VARIANT         4007
FT                   /note="P -> R (rare variant detected in a sporadic case of
FT                   Moyamoya disease in East Asian population)"
FT                   /evidence="ECO:0000269|PubMed:23110205"
FT                   /id="VAR_075640"
FT   VARIANT         4013
FT                   /note="D -> N (in MYMY2; variant detected in cases of
FT                   Moyamoya disease in Caucasian and Asian populations;
FT                   inhibitory effect on angiogenic activity of vascular
FT                   endothelial cells)"
FT                   /evidence="ECO:0000269|PubMed:21799892,
FT                   ECO:0000269|PubMed:25278557, ECO:0000269|PubMed:27736983"
FT                   /id="VAR_067024"
FT   VARIANT         4019
FT                   /note="R -> C (rare variant detected in a sporadic case of
FT                   Moyamoya disease in Caucasian population; associated with
FT                   K-4042 in cases of Moyamoya disease in Slovakian and Czech
FT                   populations; inhibitory effect on angiogenic activity of
FT                   vascular endothelial cells)"
FT                   /evidence="ECO:0000269|PubMed:25278557,
FT                   ECO:0000269|PubMed:27736983"
FT                   /id="VAR_075641"
FT   VARIANT         4042
FT                   /note="E -> K (rare variant associated with C-4019 in cases
FT                   of Moyamoya disease in Slovakian and Czech populations)"
FT                   /evidence="ECO:0000269|PubMed:27736983"
FT                   /id="VAR_079573"
FT   VARIANT         4062
FT                   /note="R -> Q (variant detected in cases of Moyamoya
FT                   disease in Caucasian populations)"
FT                   /evidence="ECO:0000269|PubMed:21799892"
FT                   /id="VAR_067025"
FT   VARIANT         4076
FT                   /note="I -> V (rare variant detected in a sporadic case of
FT                   Moyamoya disease in Asian population)"
FT                   /evidence="ECO:0000269|PubMed:25278557"
FT                   /id="VAR_075642"
FT   VARIANT         4115
FT                   /note="Missing (rare variant detected in a sporadic case of
FT                   Moyamoya disease in Caucasian population)"
FT                   /evidence="ECO:0000269|PubMed:25278557"
FT                   /id="VAR_075643"
FT   VARIANT         4118
FT                   /note="S -> F (rare variant detected in a sporadic case of
FT                   Moyamoya disease in Caucasian population)"
FT                   /evidence="ECO:0000269|PubMed:26198278"
FT                   /id="VAR_075644"
FT   VARIANT         4131
FT                   /note="R -> C (rare variant detected in a sporadic case of
FT                   Moyamoya disease in East Asian population)"
FT                   /evidence="ECO:0000269|PubMed:25956231"
FT                   /id="VAR_075645"
FT   VARIANT         4146
FT                   /note="V -> A (rare variant detected in cases of Moyamoya
FT                   disease in Slovakian and Czech populations; inhibitory
FT                   effect on angiogenic activity of vascular endothelial
FT                   cells)"
FT                   /evidence="ECO:0000269|PubMed:27736983"
FT                   /id="VAR_079574"
FT   VARIANT         4185
FT                   /note="K -> T (found in a heterozygous family with
FT                   heterogeneous intracerebral vasculopathy)"
FT                   /evidence="ECO:0000269|PubMed:25043520"
FT                   /id="VAR_075646"
FT   VARIANT         4237
FT                   /note="D -> E (rare variant detected in a sporadic case of
FT                   Moyamoya disease in Caucasian population)"
FT                   /evidence="ECO:0000269|PubMed:25278557"
FT                   /id="VAR_075647"
FT   VARIANT         4367
FT                   /note="Q -> L (rare variant detected in a sporadic case of
FT                   Moyamoya disease in East Asian population)"
FT                   /evidence="ECO:0000269|PubMed:23110205"
FT                   /id="VAR_075648"
FT   VARIANT         4399
FT                   /note="A -> T (in MYMY2; dbSNP:rs148731719)"
FT                   /evidence="ECO:0000269|PubMed:21048783,
FT                   ECO:0000269|PubMed:23110205"
FT                   /id="VAR_067026"
FT   VARIANT         4567
FT                   /note="V -> M (rare variant detected in a sporadic case of
FT                   Moyamoya disease; dbSNP:rs145282452)"
FT                   /evidence="ECO:0000269|PubMed:21048783"
FT                   /id="VAR_067027"
FT   VARIANT         4586
FT                   /note="T -> P (rare variant detected in a sporadic case of
FT                   Moyamoya disease in East Asian population)"
FT                   /evidence="ECO:0000269|PubMed:23110205"
FT                   /id="VAR_075649"
FT   VARIANT         4608
FT                   /note="P -> S (variant detected in cases of Moyamoya
FT                   disease in Caucasian populations)"
FT                   /evidence="ECO:0000269|PubMed:21799892"
FT                   /id="VAR_067028"
FT   VARIANT         4631
FT                   /note="L -> V (rare variant detected in a sporadic case of
FT                   Moyamoya disease in East Asian population)"
FT                   /evidence="ECO:0000269|PubMed:23110205"
FT                   /id="VAR_075650"
FT   VARIANT         4677
FT                   /note="W -> L (rare polymorphism)"
FT                   /evidence="ECO:0000269|PubMed:27736983"
FT                   /id="VAR_079575"
FT   VARIANT         4732
FT                   /note="K -> T (rare variant detected in a sporadic case of
FT                   Moyamoya disease in Caucasian population)"
FT                   /evidence="ECO:0000269|PubMed:25278557"
FT                   /id="VAR_075651"
FT   VARIANT         4765
FT                   /note="V -> M (rare variant detected in a sporadic case of
FT                   Moyamoya disease)"
FT                   /evidence="ECO:0000269|PubMed:21048783"
FT                   /id="VAR_067029"
FT   VARIANT         4810
FT                   /note="R -> K (in MYMY2; very frequent in individuals
FT                   affected by Moyamoya disease; strongly increases the risk
FT                   of Moyamoya disease; induces genomic instability; shows
FT                   decreased ATPase activity, possibly caused by stabilization
FT                   of the oligomeric state)"
FT                   /evidence="ECO:0000269|PubMed:21048783,
FT                   ECO:0000269|PubMed:21799892, ECO:0000269|PubMed:23110205"
FT                   /id="VAR_067030"
FT   VARIANT         4863
FT                   /note="D -> N (variant detected in cases of Moyamoya
FT                   disease in East Asian populations)"
FT                   /evidence="ECO:0000269|PubMed:21799892"
FT                   /id="VAR_067031"
FT   VARIANT         4950
FT                   /note="E -> D (variant detected in cases of Moyamoya
FT                   disease in East Asian populations and rare variant detected
FT                   in a sporadic case of Moyamoya disease)"
FT                   /evidence="ECO:0000269|PubMed:21799892,
FT                   ECO:0000269|PubMed:23110205"
FT                   /id="VAR_067032"
FT   VARIANT         5021
FT                   /note="A -> V (variant detected in cases of Moyamoya
FT                   disease in East Asian populations and rare variant detected
FT                   in a sporadic case of Moyamoya disease; dbSNP:rs138130613)"
FT                   /evidence="ECO:0000269|PubMed:21799892,
FT                   ECO:0000269|PubMed:23110205"
FT                   /id="VAR_067033"
FT   VARIANT         5136
FT                   /note="M -> I (rare variant detected in a sporadic case of
FT                   Moyamoya disease in East Asian population)"
FT                   /evidence="ECO:0000269|PubMed:23110205"
FT                   /id="VAR_075652"
FT   VARIANT         5160
FT                   /note="D -> E (variant detected in cases of Moyamoya
FT                   disease in East Asian populations)"
FT                   /evidence="ECO:0000269|PubMed:21799892"
FT                   /id="VAR_067034"
FT   VARIANT         5163
FT                   /note="V -> I (rare variant detected in a sporadic case of
FT                   Moyamoya disease in Caucasian population)"
FT                   /evidence="ECO:0000269|PubMed:25278557"
FT                   /id="VAR_075653"
FT   VARIANT         5176
FT                   /note="E -> G (variant detected in cases of Moyamoya
FT                   disease in East Asian populations)"
FT                   /evidence="ECO:0000269|PubMed:21799892"
FT                   /id="VAR_067035"
FT   MUTAGEN         2426
FT                   /note="K->A: Decreased ATPase activity"
FT                   /evidence="ECO:0000269|PubMed:24658080"
FT   MUTAGEN         2488
FT                   /note="E->A: Decreased ATPase activity"
FT                   /evidence="ECO:0000269|PubMed:24658080"
FT   MUTAGEN         2488
FT                   /note="E->Q: Loss of ATPase hydrolysis. Stabilization of
FT                   the oligomeric state. Inhibited angiogenesis"
FT                   /evidence="ECO:0000269|PubMed:26126547"
FT   MUTAGEN         2775
FT                   /note="K->A: Decreased ATPase activity"
FT                   /evidence="ECO:0000269|PubMed:24658080"
FT   MUTAGEN         2845
FT                   /note="E->A: Decreased ATPase activity"
FT                   /evidence="ECO:0000269|PubMed:24658080"
FT   CONFLICT        270
FT                   /note="M -> T (in Ref. 4; AAH36891/AAH40341)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        321
FT                   /note="M -> T (in Ref. 4; AAH36891/AAH40341)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        369
FT                   /note="K -> N (in Ref. 4; AAH36891)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1045
FT                   /note="N -> D (in Ref. 1; BAK53191 and 6; BAB13444)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1133
FT                   /note="Q -> K (in Ref. 6; BAB13444)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1195
FT                   /note="V -> M (in Ref. 6; BAB13444)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1272
FT                   /note="E -> Q (in Ref. 6; BAB13444)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1331
FT                   /note="D -> G (in Ref. 6; BAB13444)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3323
FT                   /note="R -> G (in Ref. 2; CAH56189)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4220
FT                   /note="E -> G (in Ref. 7; BAB15212)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4571
FT                   /note="D -> G (in Ref. 7; BAB15280)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4853
FT                   /note="K -> R (in Ref. 7; BAB15212)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        4892
FT                   /note="N -> S (in Ref. 7; BAB15212)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        5139
FT                   /note="L -> S (in Ref. 7; BAB15280)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        5187
FT                   /note="L -> P (in Ref. 7; BAB15330)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   5207 AA;  591407 MW;  9BA6847099EE6E08 CRC64;
     MECPSCQHVS KEETPKFCSQ CGERLPPAAP IADSENNNST MASASEGEME CGQELKEEGG
     PCLFPGSDSW QENPEEPCSK ASWTVQESKK KKRKKKKKGN KSASSELASL PLSPASPCHL
     TLLSNPWPQD TALPHSQAQQ SGPTGQPSQP PGTATTPLEG DGLSAPTEVG DSPLQAQALG
     EAGVATGSEA QSSPQFQDHT EGEDQDASIP SGGRGLSQEG TGPPTSAGEG HSRTEDAAQE
     LLLPESKGGS SEPGTELQTT EQQAGASASM AVDAVAEPAN AVKGAGKEMK EKTQRMKQPP
     ATTPPFKTHC QEAETKTKDE MAAAEEKVGK NEQGEPEDLK KPEGKNRSAA AVKNEKEQKN
     QEADVQEVKA STLSPGGGVT VFFHAIISLH FPFNPDLHKV FIRGGEEFGE SKWDSNICEL
     HYTRDLGHDR VLVEGIVCIS KKHLDKYIPY KYVIYNGESF EYEFIYKHQQ KKGEYVNRCL
     FIKSSLLGSG DWHQYYDIVY MKPHGRLQKV MNHITDGPRK DLVKGKQIAA ALMLDSTFSI
     LQTWDTINLN SFFTQFEQFC FVLQQPMIYE GQAQLWTDLQ YREKEVKRYL WQHLKKHVVP
     LPDGKSTDFL PVDCPVRSKL KTGLIVLFVV EKIELLLEGS LDWLCHLLTS DASSPDEFHR
     DLSHILGIPQ SWRLYLVNLC QRCMDTRTYT WLGALPVLHC CMELAPRHKD AWRQPEDTWA
     ALEGLSFSPF REQMLDTSSL LQFMREKQHL LSIDEPLFRS WFSLLPLSHL VMYMENFIEH
     LGRFPAHILD CLSGIYYRLP GLEQVLNTQD VQDVQNVQNI LEMLLRLLDT YRDKIPEEAL
     SPSYLTVCLK LHEAICSSTK LLKFYELPAL SAEIVCRMIR LLSLVDSAGQ RDETGNNSVQ
     TVFQGTLAAT KRWLREVFTK NMLTSSGASF TYVKEIEVWR RLVEIQFPAE HGWKESLLGD
     MEWRLTKEEP LSQITAYCNS CWDTKGLEDS VAKTFEKCII EAVSSACQSQ TSILQGFSYS
     DLRKFGIVLS AVITKSWPRT ADNFNDILKH LLTLADVKHV FRLCGTDEKI LANVTEDAKR
     LIAVADSVLT KVVGDLLSGT ILVGQLELII KHKNQFLDIW QLREKSLSPQ DEQCAVEEAL
     DWRREELLLL KKEKRCVDSL LKMCGNVKHL IQVDFGVLAV RHSQDLSSKR LNDTVTVRLS
     TSSNSQRATH YHLSSQVQEM AGKIDLLRDS HIFQLFWREA AEPLSEPKED QEAAELLSEP
     EEESERHILE LEEVYDYLYQ PSYRKFIKLH QDLKSGEVTL AEIDVIFKDF VNKYTDLDSE
     LKIMCTVDHQ DQRDWIKDRV EQIKEYHHLH QAVHAAKVIL QVKESLGLNG DFSVLNTLLN
     FTDNFDDFRR ETLDQINQEL IQAKKLLQDI SEARCKGLQA LSLRKEFICW VREALGGINE
     LKVFVDLASI SAGENDIDVD RVACFHDAVQ GYASLLFKLD PSVDFSAFMK HLKKLWKALD
     KDQYLPRKLC DSARNLEWLK TVNESHGSVE RSSLTLATAI NQRGIYVIQA PKGGQKISPD
     TVLHLILPES PGSHEESREY SLEEVKELLN KLMLMSGKKD RNNTEVERFS EVFCSVQRLS
     QAFIDLHSAG NMLFRTWIAM AYCSPKQGVS LQMDFGLDLV TELKEGGDVT ELLAALCRQM
     EHFLDSWKRF VTQKRMEHFY LNFYTAEQLV YLSTELRKQP PSDAALTMLS FIKSNCTLRD
     VLRASVGCGS EAARYRMRRV MEELPLMLLS EFSLVDKLRI IMEQSMRCLP AFLPDCLDLE
     TLGHCLAHLA GMGGSPVERC LPRGLQVGQP NLVVCGHSEV LPAALAVYMQ TPSQPLPTYD
     EVLLCTPATT FEEVALLLRR CLTLGSLGHK VYSLLFADQL SYEVARQAEE LFHNLCTQQH
     REDYQLVMVC DGDWEHCYLP SAFSQHKVFV TPQAPLEAIQ AYLAGHYRVP KQTLSAAAVF
     NDRLCVGIVA SERAGVGKSL YVKRLHDKMK MQLNVKNVPL KTIRLIDPQV DESRVLGALL
     PFLDAQYQKV PVLFHLDVTS SVQTGIWVFL FKLLILQYLM DINGKMWLRN PCHLYIVEIL
     ERRTSVPSRS SSALRTRVPQ FSFLDIFPKV TCRPPKEVID MELSALRSDT EPGMDLWEFC
     SETFQRPYQY LRRFNQNQDL DTFQYQEGSV EGTPEECLQH FLFHCGVINP SWSELRNFAR
     FLNYQLRDCE ASLFCNPSFI GDTLRGFKKF VVTFMIFMAR DFATPSLHTS DQSPGKHMVT
     MDGVREEDLA PFSLRKRWES EPHPYVFFND DHTTMTFIGF HLQPNINGSV DAISHLTGKV
     IKRDVMTRDL YQGLLLQRVP FNVDFDKLPR HKKLERLCLT LGIPQATDPD KTYELTTDNM
     LKILAIEMRF RCGIPVIIMG ETGCGKTRLI KFLSDLRRGG TNADTIKLVK VHGGTTADMI
     YSRVREAENV AFANKDQHQL DTILFFDEAN TTEAISCIKE VLCDHMVDGQ PLAEDSGLHI
     IAACNPYRKH SEEMICRLES AGLGYRVSME ETADRLGSIP LRQLVYRVHA LPPSLIPLVW
     DFGQLSDVAE KLYIQQIVQR LVESISLDEN GTRVITEVLC ASQGFMRKTE DECSFVSLRD
     VERCVKVFRW FHEHSAMLLA QLNAFLSKSS VSKNHTERDP VLWSLMLAIG VCYHASLEKK
     DSYRKAIARF FPKPYDDSRL LLDEITRAQD LFLDGVPLRK TIAKNLALKE NVFMMVVCIE
     LKIPLFLVGK PGSSKSLAKT IVADAMQGPA AYSDLFRSLK QVHLVSFQCS PHSTPQGIIS
     TFRQCARFQQ GKDLQQYVSV VVLDEVGLAE DSPKMPLKTL HPLLEDGCIE DDPAPHKKVG
     FVGISNWALD PAKMNRGIFV SRGSPNETEL IESAKGICSS DILVQDRVQG YFASFAKAYE
     TVCKRQDKEF FGLRDYYSLI KMVFAAAKAS NRKPSPQDIA QAVLRNFSGK DDIQALDIFL
     ANLPEAKCSE EVSPMQLIKQ NIFGPSQKVP GGEQEDAESR YLLVLTKNYV ALQILQQTFF
     EGDQQPEIIF GSGFPKDQEY TQLCRNINRV KICMETGKMV LLLNLQNLYE SLYDALNQYY
     VHLGGQKYVD LGLGTHRVKC RVHPNFRLIV IEEKDVVYKH FPIPLINRLE KHYLDINTVL
     EKWQKSIVEE LCAWVEKFIN VKAHHFQKRH KYSPSDVFIG YHSDACASVV LQVIERQGPR
     ALTEELHQKV SEEAKSILLN CATPDAVVRL SAYSLGGFAA EWLSQEYFHR QRHNSFADFL
     QAHLHTADLE RHAIFTEITT FSRLLTSHDC EILESEVTGR APKPTLLWLQ QFDTEYSFLK
     EVRNCLTNTA KCKILIFQTD FEDGIRSAQL IASAKYSVIN EINKIRENED RIFVYFITKL
     SRVGRGTAYV GFHGGLWQSV HIDDLRRSTL MVSDVTRLQH VTISQLFAPG DLPELGLEHR
     AEDGHEEAME TEASTSGEVA EVAEEAMETE SSEKVGKETS ELGGSDVSIL DTTRLLRSCV
     QSAVGMLRDQ NESCTRNMRR VVLLLGLLNE DDACHASFLR VSKMRLSVFL KKQEESQFHP
     LEWLAREACN QDALQEAGTF RHTLWKRVQG AVTPLLASMI SFIDRDGNLE LLTRPDTPPW
     ARDLWMFIFS DTMLLNIPLV MNNERHKGEM AYIVVQNHMN LSENASNNVP FSWKIKDYLE
     ELWVQAQYIT DAEGLPKKFV DIFQQTPLGR FLAQLHGEPQ QELLQCYLKD FILLTMRVST
     EEELKFLQMA LWSCTRKLKA ASEAPEEEVS LPWVHLAYQR FRSRLQNFSR ILTIYPQVLH
     SLMEARWNHE LAGCEMTLDA FAAMACTEML TRNTLKPSPQ AWLQLVKNLS MPLELICSDE
     HMQGSGSLAQ AVIREVRAQW SRIFSTALFV EHVLLGTESR VPELQGLVTE HVFLLDKCLR
     ENSDVKTHGP FEAVMRTLCE CKETASKTLS RFGIQPCSIC LGDAKDPVCL PCDHVHCLRC
     LRAWFASEQM ICPYCLTALP DEFSPAVSQA HREAIEKHAR FRQMCNSFFV DLVSTICFKD
     NAPPEKEVIE SLLSLLFVQK GRLRDAAQRH CEHTKSLSPF NDVVDKTPVI RSVILKLLLK
     YSFHDVKDYI QEYLTLLKKK AFITEDKTEL YMLFINCLED SILEKTSAYS RNDELNHLEE
     EGRFLKAYSP ASRGREPANE ASVEYLQEVA RIRLCLDRAA DFLSEPEGGP EMAKEKQCYL
     QQVKQFCIRV ENDWHRVYLV RKLSSQRGME FVQGLSKPGR PHQWVFPKDV VKQQGLRQDH
     PGQMDRYLVY GDEYKALRDA VAKAVLECKP LGIKTALKAC KTPQSQQSAY FLLTLFREVA
     ILYRSHNASL HPTPEQCEAV SKFIGECKIL SPPDISRFAT SLVDNSVPLL RAGPSDSNLD
     GTVTEMAIHA AAVLLCGQNE LLEPLKNLAF SPATMAHAFL PTMPEDLLAQ ARRWKGLERV
     HWYTCPNGHP CSVGECGRPM EQSICIDCHA PIGGIDHKPR DGFHLVKDKA DRTQTGHVLG
     NPQRRDVVTC DRGLPPVVFL LIRLLTHLAL LLGASQSSQA LINIIKPPVR DPKGFLQQHI
     LKDLEQLAKM LGHSADETIG VVHLVLRRLL QEQHQLSSRR LLNFDTELST KEMRNNWEKE
     IAAVISPELE HLDKTLPTMN NLISQDKRIS SNPVAKIIYG DPVTFLPHLP RKSVVHCSKI
     WSCRKRITVE YLQHIVEQKN GKERVPILWH FLQKEAELRL VKFLPEILAL QRDLVKQFQN
     VQQVEYSSIR GFLSKHSSDG LRQLLHNRIT VFLSTWNKLR RSLETNGEIN LPKDYCSTDL
     DLDTEFEILL PRRRGLGLCA TALVSYLIRL HNEIVYAVEK LSKENNSYSV DAAEVTELHV
     ISYEVERDLT PLILSNCQYQ VEEGRETVQE FDLEKIQRQI VSRFLQGKPR LSLKGIPTLV
     YRHDWNYEHL FMDIKNKMAQ DSLPSSVISA ISGQLQSYSD ACEVLSVVEV TLGFLSTAGG
     DPNMQLNVYT QDILQMGDQT IHVLKALNRC QLKHTIALWQ FLSAHKSEQL LRLHKEPFGE
     ISSRYKADLS PENAKLLSTF LNQTGLDAFL LELHEMIILK LKNPQTQTEE RFRPQWSLRD
     TLVSYMQTKE SEILPEMASQ FPEEILLASC VSVWKTAAVL KWNREMR
//
